New targeted treatment with imaging for advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (or at least 19 if you are in South Korea).
- You need to have one of these advanced cancers that has stopped responding to treatment: pancreatic, colorectal, bile duct, head and neck, esophageal, or stomach cancer.
- A special imaging scan must show that your cancer has a specific marker called NTSR1. The study team will check this.
- Your cancer must be measurable on a scan (like CT or MRI).
- You need to be in reasonably good health, able to take care of yourself (ECOG score of 2 or less).
- If you are of childbearing age, you must agree to use two effective birth control methods during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug, GSK5533524, either alone or with other treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The goal is to find a safe dose and see if it helps shrink or control the tumor.
This trial tests a new drug called SKB518 for people with advanced solid tumors that have stopped responding to standard treatments or cannot receive them. The goal is to see if SKB518 can help shrink or control the tumor.
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
This study tests a new experimental drug called MK-6204 (also known as SKB535) to see if it is safe and effective for people with certain advanced cancers that have not responded to standard treatments. The drug is given by injection and may help shrink tumors or slow their growth.
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
This trial tests a new drug called SKB500 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and may help shrink tumors.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.